CONTRIBUTORS

Behavioral Neurology and Psychiatry p. 660-666 June 2018, Vol.24, No.3 doi: 10.1212/01.CON.0000534991.24363.f5
CONTRIBUTORS
BROWSE ARTICLES
Article Level Metrics

Morris Freedman, MD, FRCPC, FAAN Guest Editor

Department of Neurology, University of Toronto; Baycrest Health Sciences; Rotman Research Institute of Baycrest Centre; Department of Neurology, Mt. Sinai Hospital, Toronto, Ontario, Canada

Relationship Disclosure: Dr Freedman serves as a trustee for the World Federation of Neurology and on the editorial boards of Brain and Cognition and Journal of Parapsychology; has received support from and served on an advisory board for Eli Lilly and Company Canada and receives publishing royalties from Oxford University Press; receives research/grant support from the Alzheimer Society of Canada, Brain Canada Foundation, Centre for Aging and Brain Health Innovation, Canadian Institutes of Health Research, and Westin Brain Institute; receives support from the Behavioural Neurology Physician Recognition Covenant Fund at Baycrest, the Morris Kerzner Memorial Fund, and the Saul A. Silverman Foundation as part of the Canada International Scientific Exchange Program project; and holds stock in companies producing or planning to produce medical marijuana and is listed on a provisional patent related to methods and kits for differential diagnosis of Alzheimer disease.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Freedman discusses the unlabeled/investigational use of medications for the treatment of aggression and agitation in dementia, none of which are approved by the US Food and Drug Administration.

Arpit Aggarwal, MD

Assistant Professor of Psychiatry, University of Missouri, Columbia, Missouri

Relationship Disclosure: Dr Aggarwal reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Aggarwal reports no disclosure.

Bruce H. Cohen, MD, FAAN

Director, NeuroDevelopmental Science Center, Akron Children’s Hospital, Akron, Ohio; Professor of Pediatrics, Northeast Ohio Medical University, Rootstown, Ohio

Relationship Disclosure: Dr Cohen serves on the board of directors of the Mitochondrial Medicine Society, on the board of trustees of the United Mitochondrial Disease Foundation, and on the editorial boards of Mitochondrion, Brain & Life, and Pediatric Neurology. Dr Cohen serves as a consultant for Stealth BioTherapeutics Inc and receives research/grant support from BioElectron Technology Corporation; Horizon Pharma plc; the National Institutes of Health (subaward 8; GG006326-03); Reata Pharmaceuticals, Inc; and Stealth BioTherapeutics Inc. Dr Cohen receives publishing royalties from Elsevier.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Cohen reports no disclosure.

H. Branch Coslett, MD, FAAN

William N. Kelley Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Coslett serves on external advisory boards for National Institutes of Health Center grants for the University of Nevada, Reno (R21 NS099645, 1R01 DC013196, R21NS089084, 1R01 NS099061) and for a US Department of Veterans Affairs grant for the VA Boston Healthcare System. Dr Coslett serves on the editorial boards of Brain and Language and Cortex and as an editor for volume 151 of the Handbook of Clinical Neurology (“The Parietal Lobe”).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Coslett reports no disclosure.

Janet Ellis, MBBChir, MD, FRCPC

Director of Psychosocial Care in Trauma, Medical Psychiatrist, Sunnybrook Health Sciences Centre; Lecturer, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Relationship Disclosure: Dr Ellis reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Ellis reports no disclosure.

Anthony Feinstein, MD, PhD

Professor of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Relationship Disclosure: Dr Feinstein serves on the editorial board of the Multiple Sclerosis Journal and receives personal compensation for speaking engagements for EMD Serono, Inc; F. Hoffman-La Roche Ltd; Novartis AG; Sanofi Genzyme; and Teva Pharmaceutical Industries Ltd. Dr Feinstein receives research/ grant support from the Multiple Sclerosis Society of Canada and publishing royalties from Amadeus Press, Cambridge University Press, and Johns Hopkins University Press.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Feinstein reports no disclosure.

Alastair Flint, MD, FRCPC, FRANZCP

Professor of Psychiatry and Vice Chair of Research, University of Toronto, Toronto, Ontario, Canada

Relationship Disclosure: Dr Flint receives research/grant support from the Alzheimer’s Association, Brain Canada Foundation, Canadian Frailty Network, Canadian Institutes of Health Research, Centre for Aging & Brain Health Innovation, National Institute of Mental Health, Ontario Brain Institute, and Patient-Centered Outcomes Research Institute.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Flint discusses the unlabeled/investigational use of D-cycloserine, gabapentin, pregabalin, propranolol, and quetiapine for the treatment of anxiety disorders.

Peter Giacobbe, MD, MSc, FRCPC

Clinical Head, Harquail Centre for Neuromodulation, Mood and Anxiety Program, Sunnybrook Health Sciences Centre; Assistant Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Relationship Disclosure: Dr Giacobbe serves on the advisory board of Janssen Canada and receives research/grant support from the Canadian Institutes of Health Research (MOP 125880, MOP 326627) and the National Institutes of Health (1R01AG042165-O1A1, 2U01MH062446-O6A2).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Giacobbe discusses the unlabeled/investigational use of D-cycloserine, gabapentin, pregabalin, propranolol, and quetiapine for the treatment of anxiety disorders.

G. Peter Gliebus, MD

Department of Neurology Interim Chairman, Assistant Professor of Neurology, Director of Behavioral Neurology and Neuropsychiatry Fellowship, Drexel University College of Medicine; Director, Cognitive Disorders Center, Drexel Neurosciences Institute, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Gliebus receives research/grant support from the Drexel Clinical and Translational Research Institute.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gliebus reports no disclosure.

Yael Goldberg, PhD, CPsych

Clinical Psychologist, Neuropsychologist, Baycrest Health Sciences, Toronto, Ontario, Canada

Relationship Disclosure: Dr Goldberg reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Goldberg discusses the unlabeled/investigational use of medications for the treatment of aggression and agitation in dementia, none of which are approved by the US Food and Drug Administration.

Murray Grossman, MDCM, FAAN

Professor of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Grossman serves as an associate editor of Neurology; as a consultant for the Association for Frontotemporal Degeneration, Bracco, and UCB, SA; and on the scientific advisory boards of the Association for Frontotemporal Degeneration and Biogen. Dr Grossman receives research/grant support from the National Institutes of Health (AG017586, AG052943, AG038490, and NS053488), and Piramal Enterprises Ltd.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Grossman reports no disclosure.

Alexandre Henri-Bhargava, MDCM, MScCH, FRCPC

Clinical Assistant Professor of Neurology, University of British Columbia; Medical Director, Neil and Susan Manning Cognitive Health Initiative, Vancouver Island Health Authority, Victoria, British Columbia, Canada

Relationship Disclosure: Dr Henri-Bhargava has received funding for clinical trials from AstraZeneca, Boehringer Ingelheim Ltd, Eli Lilly and Company, F. Hoffman-La Roche Ltd, and TauRx and has provided expert legal testimony in personal injury litigation in British Columbia.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Henri-Bhargava reports no disclosure.

David J. Irwin, MD

Assistant Professor of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

Relationship Disclosure: Dr Irwin receives research/grant support from the BrightFocus Foundation and the National Institutes of Health (K23 NS088341-01).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Irwin reports no disclosure.

Joseph S. Kass, MD, JD, FAAN

Associate Dean, Office of Student Affairs; Professor of Neurology, Psychiatry, and Medical Ethics; Director, Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine; Chief of Neurology, Ben Taub General Hospital, Houston, Texas

Relationship Disclosure: Dr Kass serves as associate editor of ethical and medicolegal issues for Continuum, as an associate editor for Continuum Audio, as a neurology section editor of Ferri’s Clinical Advisor for Elsevier, and as co-editor of Neurology Secrets, Sixth Edition. Dr Kass has received personal compensation for CME lectures from Pri-Med Medical Group and has received personal compensation as a medicolegal consultant in legal cases involving criminal cases, malpractice, and personal injury.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kass reports no disclosure.

John Lauriello, MD

Professor of Psychiatry, Department of Psychiatry Chairman, Robert J. Douglas, MD, and Betty Douglas Distinguished Faculty Scholar in Psychiatry, University of Missouri, Columbia, Missouri

Relationship Disclosure: Dr Lauriello has served as an advisor for Alkermes; Otsuka America Pharmaceutical, Inc; and Teva Pharmaceutical Industries Ltd and on the event monitoring board for Alkermes. Dr Lauriello has served on the editorial board of Academic Psychiatry. Dr Lauriello receives research/grant support from Florida Atlantic University/Otsuka America Pharmaceutical, Inc and the Missouri Foundation for Health and receives publishing royalties from Oxford University Press and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Lauriello reports no disclosure.

Jeffrey Rakofsky, MD

Assistant Professor, Director of Medical Student Education, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia

Relationship Disclosure: Dr Rakofsky receives research/grant support from ACADIA Pharmaceutics Inc; the American Board of Psychiatry and Neurology; Assurex Health; AstraZeneca; Janssen Global Services, LLC; the National Institute of Mental Health (RO1MH073719-05A1, 7R01MH104964-02); and the National Center for Complementary and Integrative Health (1UG3AT008857).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rakofsky discusses the unlabeled/investigational use of buspirone, pramipexole, and thyroid hormone as adjuncts to an antidepressant in the treatment of major depression and ketamine for treatment-resistant patients who are depressed and suicidal.

Renato T. Ramos, MD

Associate Professor of Psychiatry, University of Toronto; Staff Psychiatrist, Frederick W. Thompson Anxiety Disorders Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Relationship Disclosure: Dr Ramos reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Ramos discusses the unlabeled/investigational use of neuromodulation technology (deep brain stimulation, electroconvulsive therapy, and repetitive transcranial magnetic stimulation) and pharmacologic agents (citalopram, escitalopram, desvenlafaxine, duloxetine, mirtazapine, and venlafaxine) for the treatment of obsessive-compulsive disorder (some of which are approved for use in depression and psychosis).

Mark Rapaport, MD

Reunette W. Harris Professor and Chair, Department of Psychiatry and Behavioral Sciences, Emory School of Medicine; Chief of Psychiatric Services, Emory Healthcare, Atlanta, Georgia

Relationship Disclosure: Dr Rapaport serves as editor-in-chief of Focus: The Journal of Lifelong Learning in Psychiatry and on the editorial boards of CNS Neuroscience and Therapeutics; CNS Spectrums; Current Psychiatry; Depression Research and Treatment; Innovations in Clinical Neuroscience; Journal of Addictive Behaviors, Therapy & Rehabilitation; The Journal of Clinical Psychiatry; and Shanghai Archives of Psychiatry. Dr. Rapaport receives research/grant support from the National Center for Complementary and Integrative Health (UG3 AT008857-01, R01 AT009169-01) and the National Institute of Mental Health (MH100023-01,1R25MH101079-01).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rapaport discusses the unlabeled/investigational use of buspirone, pramipexole, and thyroid hormone as adjuncts to an antidepressant in the treatment of major depression and ketamine for treatment-resistant patients who are depressed and suicidal.

Peggy M. A. Richter, MD, FRCPC

Head, Frederick W. Thompson Anxiety Disorders Centre; Director, Clinic for Obsessive-Compulsive Disorder and Related Disorders, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Relationship Disclosure: Dr Richter serves on the editorial board of the Journal of Obsessive-Compulsive and Related Disorders, has received personal compensation for speaking engagements from Lundbeck, and receives grant/research support from the Canadian Institutes of Health Research.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Richter discusses the unlabeled/investigational use of neuromodulation technology (deep brain stimulation, electroconvulsive therapy, and repetitive transcranial magnetic stimulation) and pharmacologic agents (citalopram, escitalopram, desvenlafaxine, duloxetine, mirtazapine, and venlafaxine) for the treatment of obsessive-compulsive disorder (some of which are approved for use in depression and psychosis).

Joshua J. Rodgers, MD

Director, Behavioral Neurology & Neuropsychiatry, The Menninger Clinic; Assistant Professor of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas

Relationship Disclosure: Dr Rodgers reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rodgers reports no disclosure.

Lindsey A. Schrimpf, MD

Assistant Professor of Clinical Psychiatry, University of Missouri, Columbia, Missouri

Relationship Disclosure: Dr Schrimpf reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Schrimpf reports no disclosure.

Donald T. Stuss, OC, O Ont, PhD, FRSC, FCAHS, C Psych, ABPP-CN

University Professor Emeritus, University of Toronto; Adjunct Senior Scientist, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Relationship Disclosure: Dr Stuss serves on the advisory board of Spindle Strategy Corporation and has received personal compensation for speaking engagements for Bennett Jones LLP. Dr Stuss receives publishing royalties from Cambridge University Press.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Stuss reports no disclosure.

David F. Tang-Wai, MDCM, FRCPC

Associate Professor of Neurology and Geriatric Medicine, University of Toronto; Co-Director, University Health Network Memory Clinic, Toronto Western Hospital, Toronto, Ontario, Canada

Relationship Disclosure: Dr Tang-Wai has provided expert legal testimony for the Canadian Medical Protection Association on a case determining if a patient had cognitive impairment.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Tang-Wai reports no disclosure.

Raissa Villaneuva, MD, MPH, FAAN

Assistant Professor, Department of Neurology, University of Rochester Medical Center, Rochester, New York

Relationship Disclosure: Dr Villanueva reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Villanueva reports no disclosure.

M. Uri Wolf, MD, FRCPC

Geriatric Psychiatrist, Baycrest Health Sciences; Lecturer, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

Relationship Disclosure: Dr Wolf reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Wolf discusses the unlabeled/investigational use of medications for the treatment of aggression and agitation in dementia, none of which are approved by the US Food and Drug Administration.

Ari Zaretsky, MD, FRCPC

Professor of Psychiatry, University of Toronto; Chief, Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Relationship Disclosure: Dr Zaretsky reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Zaretsky reports no disclosure.

SELF-ASSESSMENT AND CME TEST WRITERS

James W. M. Owens Jr, MD, PhD

Associate Professor of Neurology and Adjunct Associate Professor of Pediatrics, University of Washington School of Medicine, Seattle, Washington

Relationship Disclosure: Dr Owens serves as CME co-editor for Neurology and receives publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Owens reports no disclosure.

Allison L. Weathers, MD, FAAN

Associate Chief Medical Information Offi cer, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Relationship Disclosure: Dr Weathers serves on the editorial board of Continuum and as chair of the adult neurosciences specialty steering board for Epic.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Weathers reports no disclosure.

© 2018 American Academy of Neurology